Neprilysin

Neprilysin Overview

English NameNeprilysinApproved Drugs3
Drugs in Clinical Trials8Target SynonymEC:3.4.24.11,EC 3.4.24,Atriopeptidase,NEP,SFE,Membrane Metallo-Endopeptidase (Neutral Endopeptidase, Enkephalinase, CALLA, CD10),Membrane Metallo-Endopeptidase Variant 1,Membrane Metallo-Endopeptidase Variant 2,Neprilysin-390,Neprilysin-411,CD10 Antigen,EC 3.4.24.11,CMT2T,SCA43,EPN,MME,Enkephalinase,CALLA,Neutral endopeptidase,Common acute lymphocytic leukemia antigen,Neprilysin,CD10,Membrane Metalloendopeptidase,Neutral Endopeptidase 24.11,Skin fibroblast elastase
Highest Development StageApproved
English NameNeprilysin
Target SynonymEC:3.4.24.11,EC 3.4.24,Atriopeptidase,NEP,SFE,Membrane Metallo-Endopeptidase (Neutral Endopeptidase, Enkephalinase, CALLA, CD10),Membrane Metallo-Endopeptidase Variant 1,Membrane Metallo-Endopeptidase Variant 2,Neprilysin-390,Neprilysin-411,CD10 Antigen,EC 3.4.24.11,CMT2T,SCA43,EPN,MME,Enkephalinase,CALLA,Neutral endopeptidase,Common acute lymphocytic leukemia antigen,Neprilysin,CD10,Membrane Metalloendopeptidase,Neutral Endopeptidase 24.11,Skin fibroblast elastase
Approved Drugs3
Drugs in Clinical Trials8
Highest Development StageApproved

Neprilysin Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (3)

  • Species

    Human (3)

  • Tag

    Fc Tag (1)Tag Free (1)His Tag (1)

  • Conjugate

    Unconjugated (3)

Neprilysin Background

CD10 is an endopeptidase that degrades various bioactive peptides in the extracellular matrix. In addition to enzymatic degradation, it affects multiple intracellular signal transduction pathways. CD10 expression has been extensively studied in human epithelial cancers of numerous organs and sites. CD10 expression pattern depended on the histotypes of thyroid lesions. When possible metastatic tumours and non-epithelial tumours are excluded, high CD10 expression may be useful in determining whether a primary thyroid carcinoma includes an anaplastic component.

Neprilysin Synonyms

MME,CALLA,CD10,DKFZp686O16152,MGC126681,MGC126707,NEP,SFE,Neprilysin

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
DexecadotrilPhase 3 ClinicalBioprojet PharmaGastrointestinal Diseases
Details
Sacubitril/Valsartan (Chong Kun Dang Pharmaceutical)CKD-202APhase 3 ClinicalChong Kun Dang Pharmaceutical CorpEssential Hypertension
Details
QR-12000QR-12000Phase 3 ClinicalWuhan Createrna Science and Technology Co LtdEssential Hypertension; Hypertension
Details
Debio-0827PL-37; Debio-0827Phase 2 ClinicalPharmaleadsPain
Details
SacubitrilAHU-377Phase 2 ClinicalNovartis Pharma AgCardiomyopathy, Hypertrophic; Cardiovascular Diseases; Diabetes Mellitus; Essential Hypertension; Heart Failure; Hypertension; Insulin Resistance; Metabolic Diseases
Details
Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)Phase 1 ClinicalSouthern Medical University Zhujing HospitalPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Details
Sacubitril Valsartan Sodium Extended-Relesae Tablets(Taizhou Overseas Pharma)Phase 1 ClinicalTaizhou Overseas Pharmaceuticals Co LtdHeart Failure
Details
Sacubitril/Allisartan Isoproxil/Amlodipine BesylatePhase 1 ClinicalShenzhen Salubris Pharmaceuticals Co LtdEssential Hypertension
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Sacubitril/Allisartan IsoproxilAHU-377/EXP3174; S-086ApprovedShenzhen Salubris Pharmaceuticals Co Ltd信超妥Mainland ChinaEssential HypertensionShenzhen Salubris Pharmaceuticals Co Ltd2025-05-20Essential Hypertension; Heart Failure; Hypertension
Details
Sacubitril/Valsartan Sodium HydrateLCZ-696; LCZ-696AApprovedNovartis Pharma AgENTRESTO SPRINKLE, Enresuto, Enrest, Entresto, Neparvis, 诺欣妥, 科畅欣United StatesHeart FailureNovartis Pharmaceuticals Corp2015-07-07Breast Neoplasms; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Erectile Dysfunction; Essential Hypertension; Heart Defects, Congenital; Heart Diseases; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Hepatic Insufficiency; Hypertension; Lymphoma; Myocardial Infarction; Obesity; Peripheral Arterial Disease; Postmyocardial Infarction Syndrome; Renal Insufficiency; Renal Insufficiency, Chronic; Ventricular Dysfunction, Left
Details
RacecadotrilTiorfan; HidrasecApprovedBioprojet PharmaFranceDiarrheaBioprojet Pharma1993-03-23Diarrhea; Diarrhea, Infantile; Sepsis
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland